Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O43617
UPID:
TPPC3_HUMAN
Alternative names:
BET3 homolog
Alternative UPACC:
O43617; A6NDN0; B2RDN2; D3DPS2
Background:
Trafficking protein particle complex subunit 3, also known as BET3 homolog, is implicated in the crucial process of vesicular transport from the endoplasmic reticulum to the Golgi apparatus. This protein plays a pivotal role in maintaining the efficiency and specificity of intracellular transport, a fundamental aspect of cellular operation and homeostasis.
Therapeutic significance:
Understanding the role of Trafficking protein particle complex subunit 3 could open doors to potential therapeutic strategies. Its involvement in vesicular transport mechanisms positions it as a key player in cellular biology, with implications for diseases where these processes are disrupted.